EU OKs low-dose Xarelto to prevent recurrent VTE
A lower dose formulation of Bayer and Janssen’s bloodthinner Xarelto has been approved by European regulators for preventing recurrent venous thromboembolism, expanding treatment options for patients.
Read More
